ARTICLES LIST

Clear Search

Select the Article Source National Cancer Institute Office of Dietary Supplements National Institute on Aging Healthfinder.gov National Institute of Child Health and Human Development Centers for Disease Control and Prevention Administration for Children and Families National Institute of Environmental Health Sciences National Library of Medicine National Institute of Allergy and Infectious Diseases National Center for Complementary and Integrative Health National Institute of Neurological Disorders and Stroke NIH Senior Health National Institute of Arthritis and Musculoskeletal and Skin Diseases Health and Human Services National Institute of General Medical Sciences National Institute of Dental and Craniofacial Research National Human Genome Research Institute Food and Drug Administration Center for Tobacco Products Public Health and Medical Emergency Support for a Nation Prepared Office of Disease Prevention and Health Promotion, Healthy People National Institute on Drug Abuse National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases U S Food and Drug Administration National Institute on Deafness and Other Communication Disorders National Heart, Lung, and Blood Institute

Media ID	Source Name	Media Type	Language	Media Name	Media Description	Keywords	Keywords	Link to Article
1480	National Cancer Institute	Html	en	Gastric Cancer Treatment (PDQ®)–Health Professional Version	Expert-reviewed information summary about the treatment of gastric cancer.	median survival 0.63157 Three-year overall survival 0.637349 postoperative chemotherapy 0.607291 evidence 0.599884 S-1 group 0.532476 United States 0.629181 IIIB gastric cancer 0.571507 gastric cancer resection 0.57432 adjuvant chemoradiation therapy 0.846798 trial 0.61074 Postoperative chemoradiation therapy 0.558554 adjuvant combined modality 0.6554 total gastrectomy 0.60297 3-year OS rate 0.544309 3-year OS rates 0.626301 postoperative combined chemoradiation 0.551401 median follow-up 0.535007 therapy versus surgery 0.546551 chemoradiation therapy group 0.623893 significantly higher likelihood 0.622742 postoperative chemoradiation regimen 0.637796 noncardia gastric cancers 0.63288 surgery-only group 0.537222 relapse-free survival rates 0.794523	3-year OS 0.717532 gastroesophageal junction 0.570534 disease-free survival rate 0.550481 gastric cancer 0.998454 progression-free survival 0.57907 patients 0.884826 Neoadjuvant chemoradiation therapy 0.554541 metastatic gastric cancer 0.697572 curative intent 0.539619 significant survival benefit 0.6365 prospective multi-institution phase 0.543154 surgery-alone arm 0.607016 proximal subtotal gastrectomy 0.57677 perioperative chemotherapy group 0.806838 lymph nodes 0.576141 completely resected stage 0.638305 chemoradiation therapy 0.899775 hazard ratio 0.57654 regional lymph nodes 0.559708 Level 0.600335 chemoradiation therapy versus 0.543268 phase III trial 0.597716 3-year disease-free survival 0.564109	CLICK HERE
1612	National Cancer Institute	Html	en	Transitional Cell Cancer of the Renal Pelvis and Ureter Treatment (PDQ®)–Patient Version	Expert-reviewed information summary about the treatment of renal pelvis and ureter transitional cell cancer.	general cancer information 0.245004 treatment 0.36943 cancer treatment 0.274834 new cancer treatments 0.244453 NCI-supported cancer 0.252295 cancer cells 0.305937 cancer spreads 0.254859 body 0.283889 diagnose transitional cell 0.268084 Cancer Information Service 0.245843 PDQ cancer information 0.2892 Recurrent transitional cell 0.259741 segmental resection 0.252407 kidney 0.248946 clinical trial search 0.276195 treatment clinical trials 0.260027 National Cancer Institute 0.300743 clinical trials 0.500017 Ureter Treatment 0.280286 metastatic transitional cell 0.241447 PDQ Transitional Cell 0.249302 cancer information summary 0.272322 clinical trial 0.418117 new treatment 0.269914	breast cancer prevention 0.240544 renal cell cancer 0.301024 ureter 0.545878 patients 0.265691 Blood. The cancer 0.243945 Cell Cancer Treatment 0.266901 PDQ summary 0.241392 treatment clinical trial 0.245285 kidney cancer 0.240494 NCI PDQ cancer 0.250983 cancer research process 0.24139 cancer clinical trials 0.286739 tests 0.24917 stage 0.247801 certain pain medicines 0.268283 tumor 0.244567 treatment options 0.255801 cancer information summaries 0.244613 Treatment Editorial Board 0.244593 comprehensive cancer information 0.244987 renal pelvis 0.969529 standard treatment 0.251972 General information 0.241791	CLICK HERE
1719	National Cancer Institute	Html	en	Sentinel Lymph Node Biopsy	A fact sheet that describes the sentinel lymph node biopsy procedure and details two clinical trials evaluating the effectiveness of this procedure.	breast cancer cells 0.207523 additional lymph nodes 0.324919 lymph node dissection 0.365902 cancer cells 0.313838 completion lymph node 0.32082 additional lymph node 0.319225 sentinel node 0.255614 clinical trials 0.22069 adjuvant systemic therapy 0.201592 nearby lymph nodes 0.410736 regional lymph node 0.311853 lymph vessels 0.353059 extensive lymph node 0.426951 lymph node removal 0.331582 sentinel lymph nodes 0.328406 external-beam radiation therapy 0.223044 positive sentinel lymph 0.331906	lymph node biopsy 0.364124 sentinel lymph node 0.877175 breast cancer 0.260519 negative axillary lymph 0.276414 fewer lymph nodes 0.321344 multiple lymph nodes 0.309038 SLNB 0.244263 lymph node involvement 0.373283 lymph fluid 0.290316 axillary lymph node 0.386593 lymph nodes 0.832406 additional nearby lymph 0.283578 lymph node 0.99204 lymph node surgery 0.535704 regional lymph nodes 0.405136 cancer 0.32073 lymph node metastasis 0.429092	CLICK HERE
1822	National Cancer Institute	Html	es	Tratamiento del linfoma no Hodgkin infantil (PDQ®)–Versión para profesionales de salud	Resumen de información revisada por expertos acerca del tratamiento del linfoma no Hodgkin infantil.	LNH sobrevivirán 0.259398 Zimmermann M 0.292078 Pediatric Non-Hodgkin Lymphoma 0.307431 with b-cell 0.245734 células t 0.360685 large cell lymphoma 0.592792 large b-cell lymphoma 0.310638 Burkitt lymphoma 0.390944 anaplastic large-cell lymphoma 0.391142 B-cell lymphoma treated 0.259053 Gerrard M 0.253938 Burkitt's lymphoma 0.311811 Non-Hodgkin Lymphoma Staging 0.255329 linfoma folicular tipo 0.251963 childhood t-cell lymphoblastic 0.240771 Leuk Lymphoma 0.317156 Perkins SL 0.288471 childhood cancer 0.239116 or relapsed lymphoma 0.247628 malignant lymphoma 0.246238 Sposto R 0.298634 Non-Hodgkin Lymphoma Response 0.260692 patients with lymphoma 0.260427 group study 0.273614 estadio iv 0.240422	Cairo MS 0.242979 Pediatr Blood Cancer 0.510662 tipo burkitt células 0.244366 Cancer Group Study 0.240733 lymphoblastic lymphoma 0.400773 Clin Oncol 0.804352 B-cell non-Hodgkin 0.317262 sistema nervioso central 0.275043 childhood b-cell 0.244175 lymphoma kinase-positive 0.244682 non-hodgkin lymphoma 0.692526 Children's Cancer Group 0.319924 lymphoma clinical trials 0.248853 b-cell lymphoma 0.27822 tipo burkitt 0.265416 non-hodgkin's lymphoma 0.96423 mediastinal b-cell lymphoma 0.256031 group report 0.255665 children's oncology group 0.421119 anaplastic large cell 0.389279 Burkitt's lymphoma from 0.271141 lymphoma with tumor 0.259565 células b 0.2577 Burkhardt B 0.329473	CLICK HERE
1893	National Cancer Institute	Html	es	Tratamiento de la leucemia linfoblástica aguda infantil (PDQ®)–Versión para pacientes	Resumen de información revisada por expertos acerca del tratamiento de la leucemia linfoblástica aguda infantil.	posibles efectos tardíos 0.502603 células madre 0.665076 posibles factores 0.501536 adultos jóvenes 0.501533 leucemia linfocítica aguda 0.512291 alto riesgo 0.502688 Neurofibromatosis tipo 0.502438 leucemia linfoblástica aguda 0.9746 células madre formadoras 0.506563 siguientes especialistas 0.501875 hueso compacto 0.506303 neoplasias mieloides 0.501904 remisión ayuda 0.501645 enlace drugs approved 0.513331 cromosoma filadelfia 0.525108 célula madre mieloide 0.512145 células mieloides 0.511482 células t 0.515919 efectos tardíos 0.512683 Acute Lymphoblastic Leukemia 0.513739 PDQ Efectos tardíos 0.504379 líquido cefalorraquídeo 0.536807	punción espinal.Ampliar 0.501851 National Cancer Institute 0.501144 Instituto Nacional 0.503927 célula madre linfoide 0.505893 PDQ Tratamiento 0.503921 leucemia mielógena 0.507289 siguientes signos 0.502333 nuevos tipos 0.501266 Physician Data Query 0.504088 sistema nervioso central 0.50205 linfocitos t 0.507752 siguientes terapias 0.501163 leucemia mieloide aguda 0.536874 siguientes enlaces 0.501056 célula madre 0.527864 células sanguíneas maduras 0.513427 analizarse.Este procedimiento 0.501709 consolidación /intensificación 0.531485 Filadelfia".Ampliar Cromosoma Filadelfia 0.504086 ósea elabora células 0.51533 siguientes sumarios 0.503486 siguientes pruebas 0.502205	CLICK HERE
1918	National Cancer Institute	Html	es	Tratamiento del cáncer de vías biliares (colangiocarcinoma) (PDQ®)–Versión para pacientes	Resumen de información revisada por expertos acerca del tratamiento del cáncer de vías biliares.	pequeñas incisiones 0.429743 siguientes procedimientos 0.496942 pequeño número 0.430642 estadio iv 0.806715 IIIB.Estadio IIIA 0.428895 siguientes afecciones 0.443112 siguientes tipos 0.469726 múltiples tumores 0.426811 rayos x 0.429804 estadio ivb 0.620663 llama estadificación 0.509816 vías extrahepáticas distal 0.500664 rama derecha 0.425053 biliares extrahepáticas distal 0.562053 estadio iva 0.611281 quimioterapia sistémica 0.540152 National Cancer Institute 0.425091 quimioterapia sistémica ayuda 0.448855 colangiocarcinomas.ampliar anatomía 0.433411 estadios iiia 0.428062	siguientes riesgos 0.418955 estadio iib.estadio iia 0.483131 Instituto Nacional 0.443118 PDQ Tratamiento 0.452416 siguientes grupos 0.435798 vías biliares.Cáncer 0.522502 Colangiopancreatografía retrógrada 0.432583 marcador tumoral ca 0.457024 color arcilla 0.428813 fosfatasa alcalina 0.43337 siguientes factores 0.436523 partes distantes 0.435203 Physician Data Query 0.487514 estadio ib.estadio ia 0.481572 estadio iii 0.699586 antígeno carcinoembrionario 0.500245 biliar extrahepático distal 0.995606 medicamentos radiosensibilizadores 0.497933 pequeños conductos 0.46338 estadio ivb.estadio iva 0.489932	CLICK HERE
3443	National Cancer Institute	Html	es	Prevención del cáncer de cavidad oral y orofaringe (PDQ®)–Versión para pacientes	Sumario de información revisada por expertos sobre factores que pueden influir en el riesgo de presentar cáncer de labio, cavidad oral y orofaringe, y sobre las investigaciones dirigidas a prevenir esta enfermedad.	área pequeña detrás 0.802445 mastique betel 0.744682 Visuals Online 0.640815 voluntarios sanos 0.673012 rojo anormal 0.920245 Physician Data Query 0.914313 suficiente ejercicio 0.702729	prevención revisa 0.679375 siguientes tejidos 0.731332 PDQ Prevención 0.725434 National Cancer Institute 0.673463 siguientes riesgos 0.652028 Instituto Nacional 0.74458	CLICK HERE
3454	National Cancer Institute	Html	es	Grados de comprobación científica de los estudios de terapias integrales, alternativas y complementarias en seres humanos con cáncer (PDQ®)–Versión para profesionales de salud	Información acerca de cómo evaluar la solidez de los datos probatorios obtenidos de los estudios de investigación sobre terapias integrales, alternativas y complementarias en seres humanos con cáncer.	Visuals Online 0.6561 grupo control 0.658003 Physician Data Query 0.707803 distintos tipos 0.676327 mejores casos— 0.670195 valoración indirectos 0.860816 tratamiento versus muerte 0.748944	National Cancer Institute 0.697449 personas ayuda 0.673043 siguientes riesgos 0.659857 mejores casos 0.807578 versus muerte 0.798627 Instituto Nacional 0.960893	CLICK HERE
16599	National Cancer Institute	Html	es	Actividad física y cáncer	Hoja informativa que resume la evidencia que relaciona el ejercicio y otras actividades físicas, incluso el trabajo y tareas domésticas, para reducir los riesgos de cáncer.	physical activity trials 0.609757 with risk 0.60318 12). La actividad 0.606743 actividad física. Estas 0.606316 British Journal 0.604503 Jochem C 0.601681 Breast Cancer Research 0.606153 Leitzmann MF 0.603331 vigorous physical activity 0.609704 Polyp Prevention Trial 0.601597 mortality among breast 0.602477 physical activity guidelines 0.609758 physical activity with 0.609915 postdiagnosis physical activity 0.608948 7). La actividad 0.606768 Internal Medicine 0.603799 distal colon cancers 0.601731 actividad física 0.987182 PubMed Abstract 0.847996 NIH-AARP Diet 0.601986 Clinical Oncology 0.601841 Cancer Journal 0.605637 International Journal 0.60436 Courneya KS 0.60156 Does physical activity 0.60988	actividad física. La 0.606304 Arem H 0.601596 cancer prevention 0.614687 Schmid D 0.60334 semana. La actividad 0.606319 British Medical Journal 0.601693 Behrens G 0.608768 física causa cáncer 0.609492 gastrointestinal cancers 0.608366 Health Study 0.605366 Cancer Research 0.607712 actividad física. Sin embargo 0.606177 reducción promedio 0.602018 breast cancer 0.663645 Cancer Survivorship 0.604816 systematic review 0.658042 Keimling M 0.603345 physical activity 0.836944 Eliassen AH 0.601741 mejores resultados 0.60425 Cancer Institute 0.60845 Colditz GA 0.601647 Ballard-Barbash R 0.60156 recreational physical activity 0.616085	CLICK HERE
16695	National Cancer Institute	Html	en	Exceptional Responders Initiative: Questions and Answers	NCI has embarked on the Exceptional Responders Initiative to understand the molecular underpinnings of exceptional responses to treatment, primarily via chemotherapy, in cancer patients.	Available tumor tissue 0.569626 interpretable sequencing data 0.508921 molecular characterization data 0.448382 tissue 0.682864 exceptional response 0.726518 clinical data 0.520236 additional medical conditions 0.442297 Genome Sequencing 0.47304 NCI Adult CIRB 0.443946 bladder cancer 0.458992 advanced sequencing techniques 0.482454 clinical trials 0.50225 Exceptional Responders Initiative 0.704836 clinical trial 0.614538 usable genomic sequencing 0.494954 mRNA sequencing 0.489887 prior tissue 0.461175 patients 0.547684 normal tissue 0.467725 malignant tissue 0.514104 genomic sequencing data 0.583786 Exceptional Responders study 0.609387 exceptional responder definition 0.533195 tissue needs 0.459244	tumor tissue 0.673639 exceptional responses 0.550034 exceptional responder case 0.637888 Web-based clinical data 0.459426 later-phase clinical trials 0.47033 responder case identification 0.442725 National Cancer Institute 0.44916 Exceptional Responders Data 0.587384 partial response 0.553124 Tumor treatment history 0.473817 complete response 0.575098 Response Evaluation Criteria 0.47452 exceptional responders 0.907488 Core Resource facility 0.528106 Data Access Request 0.442704 interpretable genomic sequencing 0.494665 clinical trial data 0.50513 paraffin-embedded tissue 0.442416 similarly treated patients 0.476935 clinical research data 0.463293 certain molecular features 0.447952 potential exceptional responder 0.522095 whole-exome sequencing 0.464948 Biospecimen Core Resource 0.534633	CLICK HERE